PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引：91
|
作者：
Hirsch, Laure [1 ]
Zitvogel, Laurence [2 ]
Eggermont, Alexander [3 ]
Marabelle, Aurelien [1 ,2 ]
机构：
[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France
[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France
来源：
BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 01期
关键词：
OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;
D O I：
10.1038/s41416-018-0294-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.
引用
收藏
页码：3 / 5
页数：3
相关论文
共 50 条
  • [21] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [22] Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Shergold, Amy L.
    Millar, Rhona
    Nibbs, Robert J. B.
    PHARMACOLOGICAL RESEARCH, 2019, 145
  • [23] PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
    Long Jia
    Qi Zhang
    Rongxin Zhang
    Cancer Biology & Medicine, 2018, 15 (02) : 116 - 123
  • [24] PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
    Long Jia
    Qi Zhang
    Rongxin Zhang
    Cancer Biology & Medicine, 2018, (02) : 116 - 123
  • [25] PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
    Jia, Long
    Zhang, Qi
    Zhang, Rongxin
    CANCER BIOLOGY & MEDICINE, 2018, 15 (02) : 116 - 123
  • [26] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [27] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [28] The PD-1/PD-L1 Pathway in Human Pathology
    Saresella, M.
    Rainone, V.
    Al-Daghri, N. M.
    Clerici, M.
    Trabattoni, D.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (03) : 259 - 267
  • [29] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [30] Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
    Ding, Lei
    Lu, Shengdi
    Li, Yanli
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (02) : 651 - 663
12345